Publications by authors named "P Szopinski"
Andexanet alfa (AA) is a recombinant inactive analog of human activated factor X (FXa), effectively reversing the effects of its inhibitors - rivaroxaban and apixaban, which are available in Poland. The drug was approved for clinical use registration after the publication of the results of the ANNEXA-4 trial (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXa Inhibitors 4), in which its efficacy in restoring hemostasis in life-threatening hemorrhages in patients receiving using the aforementioned anticoagulants was demonstrated. Hence, AA is now recommended for patients on apixaban or rivaroxaban therapy with massive and uncontrollable hemorrhages, including hemorrhagic strokes (HS) and gastrointestinal bleeding.
View Article and Find Full Text PDFObjective: To report results of application a new stent graft design for the treatment of patients with thoraco-abdominal aneurysms (TAAAs), which was co-invented by a vascular surgeon. This is a retrospective observational study.
Methods: The Colt is a self-expanding stent graft, composed of nitinol metal stents creating a special exoskeleton with asymmetric springs covered with polyester material.
Article Synopsis
- EVAS (Endovascular Aneurysm Sealing) was introduced in 2013 but faced issues with device migration and type Ia endoleaks, leading to recalls and a need for alternative treatments.
- The authors reported on 20 procedures from 2014 to 2021 involving failed EVAS in male patients aged 65-79, detailing experiences with three management techniques for complications.
- In total, seven Nellix explantations occurred, with varying outcomes: some patients had successfully managed complications, while one patient ultimately died from postoperative complications.
Purpose: This study investigated the 2-year safety and effectiveness of the PQ Bypass DETOUR system as a percutaneous femoropopliteal bypass.
Materials And Methods: Seventy-eight patients with 82 long-segment femoropopliteal lesions were enrolled in this prospective, single-arm, multicenter study. The DETOUR system deployed Torus stent grafts directed through a transvenous route.